Mutiara Rahmah Amari

Mutiara Rahmah Amari

Auto-generated profile, based on publicly available information

Mutiara Rahmah Amari

Fatmawati Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
MAMutiara Rahmah Amari
Mutiara Rahmah Amari
HWhesti lina wiraswati
hesti lina wiraswati
Nisa FauziahNisa Fauziah
Nisa Fauziah
IMIlma Fauziah Ma'ruf
Ilma Fauziah Ma'ruf
Plasmodium falciparum is the most common species of Plasmodium that causes malaria in Southeast Asia. Artemisinin, a drug with the mechanism of action by inducing oxidative stress in infected red blood cells (RBC) is currently used as the main therapy for malaria, after resistance to chloroquine has been found. However, evidence of artemisinin resistance was discovered in several regions in Southeast Asia. Therefore, a research is required to prove the existence of other drugs that have anti-malaria effects. A drug candidate, doxorubicin also can induce the formation of oxidative stress inside the cells. This study aims to determine the activity of doxorubicin to inhibit the development of P. falciparum in vitro. Red blood cell (RBC) infected with P. falciparum were treated with various concentrations of doxorubicin. Giemsa technique was applied to detect P. falciparum inside RBC. After 48 hours of incubation, the culture was observed to measure the number and the confluence of RBC and P. falciparum in the medium. This study revealed that doxorubicin reduced the number of RBC infected with P. falciparum lysis. The effective dose of doxorubicin-inhibit RBC cell lysis is 0.4 μM, which only reduces 81% RBC cell lysis compared to the control group that reduces 95% RBC cell lysis. At this concentration also found a decrease in the number of P. falciparum cells in the medium. The results proved that doxorubicin has an inhibitory effect on the development of P. falciparum and can decrease the lysis of RBC due to P. falciparum infection. This findings provide an insight that doxorubicin is a potential candidate for antimalarial drugs.

24 September 2026 in Research Square
Verified
Preprint
Open access
PDF file
RMRadhiyatam Mardhiyah
Radhiyatam Mardhiyah
AAAnna Ariane
Anna Ariane
SUSumariyono
Sumariyono
KSKanadi Sumapraja
Kanadi Sumapraja
RSRobert Sinto
Robert Sinto
MAMutiara Rahmah Amari
Mutiara Rahmah Amari
Background . Systemic lupus erythematosus (SLE) predominantly affects women of reproductive age and may be accompanied by menstrual and reproductive dysfunction. Menstrual disturbances may raise concerns regarding premature ovarian insufficiency (POI), a condition characterized by menstrual disturbances accompanied by biochemical evidence of ovarian insufficiency, typically reflected by elevated serum follicle-stimulating hormone (FSH) levels. However, menstrual abnormalities do not necessarily indicate ovarian insufficiency. Objective . To evaluate menstrual disturbances and serum follicle-stimulating hormone (FSH) findings among reproductive-aged women with SLE and to explore their associations with SLE disease activity and cyclophosphamide exposure. Methods . This cross-sectional study included 175 consecutively recruited women with SLE aged 18–39 years. Menstrual history was assessed by direct interview to identify oligomenorrhea or amenorrhea. Serum FSH was measured in participants with menstrual disturbances. Disease activity was evaluated using high disease activity status (HDAS), defined as SLEDAI-2K ≥ 10, and cyclophosphamide exposure was obtained from medical records. Associations with menstrual disturbances were assessed using bivariate analyses and an exploratory multivariable logistic regression model. Results . Thirty of 175 participants (17.1%) reported oligomenorrhea or amenorrhea. Among these 30 participants, median serum FSH was 5.24 IU/L (range 1.90-20.71 IU/L), and none had an FSH concentration > 25 IU/L. HDAS was more frequent among participants with menstrual disturbances than among those without menstrual disturbances (50.0% vs 26.9%; p = 0.013). In exploratory multivariable analysis adjusted for age and prior cyclophosphamide exposure, HDAS remained associated with menstrual disturbances (adjusted OR 2.75, 95% CI 1.18–6.38; p = 0.019). Prior cyclophosphamide exposure was not significantly associated with menstrual disturbances (13.3% vs 9.7%; p = 0.517). Conclusion . Menstrual disturbances were observed in approximately one-sixth of reproductive-aged women with SLE and were associated with high disease activity. However, elevated serum FSH concentrations suggestive of ovarian insufficiency were not observed among symptomatic participants. The association between cyclophosphamide exposure and menstrual dysfunction remains inconclusive because few participants had received cyclophosphamide and cumulative doses were predominantly low. Longitudinal studies incorporating serial hormonal assessment are needed to better characterize reproductive dysfunction in women with SLE.